Acute Chest Syndrome: Clinical Trials

7 trials for Acute Chest Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 recruiting, 2 terminated, 1 withdrawn. 7 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 37Completed 2, Recruiting 2, Terminated 2, Withdrawn 1
Phase 21Completed 1

Follow Acute Chest Syndrome: new trials by email Literature Review of Acute Chest Syndrome trials Research Report on Acute Chest Syndrome

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease
Lidocain, Placebo, Standard of care - Vaso-Occlusive Pain Episode in Sickle Cell Disease
Phase 3RecruitingNantes University Hospital1042026-07-032026-09-09
Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease
Tocilizumab (RoActemra®, 20 mg/mL)., Placebo (NaCl 0.9%) - Sickle Cell Disease, Acute Chest Syndrome
Phase 3RecruitingAssistance Publique - Hôpitaux de Paris1302025-08-272026-06-24
Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing Vaso-Occlusive Crises Rate in Pediatric Patients With Sickle Cell Disease.
Brilinta, Placebo - Sickle Cell Disease
Phase 3WithdrawnAstraZeneca2020-06-302020-07-15
Effect of Platelet Inhibition and / or Lipid Lowering in Non-ACS-patients With Positive Troponin
Aspirin, Atorvastatin, Placebo Aspirin - Acute Chest Syndrome
Phase 3TerminatedDr. med. Mahir Karakas682020-02-212022-05-24
Therapeutic Anticoagulation Strategy for Acute Chest Syndrome
Prophylactic anticoagulation ( INNOHEP®), Curative anticoagulation ( INNOHEP®) - Anemia, Sickle Cell
Phase 3CompletedAssistance Publique - Hôpitaux de Paris1982016-12-162024-02-09
Effect of Inhaled Nitric Oxide in Acute Chest Syndrome (INOSTA Study)
Nitric Oxide, Placebo - Sickle Cell Disease, Acute Chest Syndrome
Phase 2 / Phase 3CompletedAssistance Publique - Hôpitaux de Paris1002008-12-012013-08-02
Dexamethasone to Treat Acute Chest Syndrome in People With Sickle Cell Disease
Dexamethasone, Placebo - Anemia, Sickle Cell
Phase 3TerminatedChildren's Hospital Medical Center, Cincinnati122006-12-012013-04-09

Narrower conditions

Anemia, Sickle Cell (6)  ·  Vaso-Occlusive Crises (2)  ·  Acute Lung Injury (1)  ·  Agnosia (1)  ·  Anemia (1)  ·  Rare Diseases (1)

Broader conditions

Anemia, Hemolytic (7)  ·  Anemia, Hemolytic, Congenital (7)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7)  ·  Genetic Diseases, Inborn (7)  ·  Hematologic Diseases (7)  ·  Hemic and Lymphatic Diseases (7)  ·  Hemoglobinopathies (7)  ·  Lung Diseases (7)  ·  Respiration Disorders (7)  ·  Respiratory Tract Diseases (7)  ·  Anemia (6)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Anemia, Sickle Cell (1)  ·  Disease Attributes (1)  ·  Lung Injury (1)

Interventions

Aspirin (1)  ·  Atorvastatin (1)  ·  Dexamethasone (1)  ·  Hydroxymethylglutaryl-CoA Reductase Inhibitors (1)  ·  Nitric Oxide (1)  ·  Sodium Chloride (1)  ·  Standard of Care (1)  ·  Ticagrelor (1)  ·  Tinzaparin (1)  ·  tocilizumab (1)

Sponsors

Assistance Publique - Hôpitaux de Paris (3)  ·  AstraZeneca (1)  ·  Children's Hospital Medical Center, Cincinnati (1)  ·  Dr. med. Mahir Karakas (1)  ·  Nantes University Hospital (1)

Countries

France (4)  ·  Germany (1)  ·  Guadeloupe (1)  ·  United States (1)

Top investigators

Anders Berggren, MD, PhD (1)  ·  Armand Mekontso Dessap, MD, PhD (1)  ·  Bernard Maitre, MD, PhD (1)  ·  Charles Quinn, MD (1)  ·  Mahir Karakas, MD (1)

Results publications

PMID 21848879, PMID 26431718, PMID 40209087

NIH funding

2023 (1), U54HL070587 (1)